On November 15, 2021 iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System, reported a research collaboration with the University of Texas Southwestern Medical Center ("UT Southwestern") to explore in solid tumors the anti-cancer potential of the molecule that is part of the IBIO-100 program (Press release, iBioPharma, NOV 15, 2021, View Source [SID1234595596]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Among all the stromal cells that present in the tumor microenvironment, cancer-associated fibroblasts ("CAFs") are one of the most abundant and critical components of tumor tissue, which provide physical support for tumor cells and can promote or retard tumorigenesis in a context-dependent manner. CAFs are also involved in the modulation of many components of the immune system, and recent studies have revealed their roles in immune evasion and poor responses to cancer immunotherapy.1 In addition, CAF response to chemotherapy is highly variable.2
Through a series of planned in vitro and in vivo studies, the collaboration will evaluate the potential of the anti-fibrotic effects of iBio’s endostatin E4 molecule to improve the efficacy of concomitant treatments, such as chemotherapy and immunotherapy, in cancer models with a fibrotic component. The Company is currently developing endostatin E4 as IBIO-100 for fibrotic diseases.
"We are thrilled to combine our efforts with one of the world’s leading fibrotic tumor cancer research labs at one of the premier academic medical centers in the nation," said Tom Isett, Chairman and Chief Executive Officer at iBio. "IBIO-100 has shown strong therapeutic potential in preclinical models of two major fibrotic diseases, systemic scleroderma and idiopathic pulmonary fibrosis, and we look forward to exploring these same potentially transformative benefits in the treatment of solid tumors."
"Through many years of research, we have come to understand that an overabundant fibrotic tumor microenvironment is associated with poor cancer treatment outcomes," commented Martin Brenner, DVM. Ph.D., iBio’s Chief Scientific Officer. "We have also learned that destruction of CAFs can lead to worse prognosis, not better.3 We believe that our endostatin E4 molecule has the potential to normalize fibrosis without the detrimental effects of CAF destruction, thereby improving responses to current standard of care treatments such as chemotherapy and immunotherapy. We look forward to exploring this potential with our partners at UT Southwestern."